Street Calls of the Week
AngioDynamics (NASDAQ:ANGO) SVP and Chief Legal Officer Lawrence T. Weiss reported purchasing 10,000 shares of the company’s common stock on October 21, 2025. The shares were bought at a weighted average price of $11.81, for a total transaction value of $118,100. Prices paid ranged from $11.71 to $11.90. The purchase comes as the stock shows strong momentum, with a 59% return over the past year and 24% gain in the last six months, according to InvestingPro data. Following the transaction, Weiss directly owns 93,597 shares of AngioDynamics , representing a significant position in the $482 million market cap company. InvestingPro analysis shows the company maintains a GOOD financial health score, with analyst price targets ranging from $16 to $24. Get access to 7 more exclusive ProTips and comprehensive insider trading analysis with InvestingPro’s detailed research reports.
In other recent news, AngioDynamics reported its fiscal first quarter 2026 financial results, revealing net sales of $75.7 million, which marked a 12.2% year-over-year growth. The company’s earnings per share (EPS) were -$0.10, surpassing the expected -$0.12. AngioDynamics’ Med Tech segment generated $35.3 million in sales, a 26.1% increase from the previous year, while the Med Device segment contributed $40.4 million, up 2.3%. Analysts from H.C. Wainwright reiterated a Buy rating for AngioDynamics, setting a price target of $16.00, reflecting confidence in the company’s performance. Additionally, Canaccord Genuity raised its price target for the company to $18.00 from $17.00, maintaining a Buy rating. This decision was influenced by AngioDynamics’ strong first-quarter performance and progress toward positive cash flow for fiscal year 2026. These developments indicate a positive outlook from analysts regarding AngioDynamics’ financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.